Anti-BTLA(tifcemalimab biosimilar) mAb

Cat. No. BME100695

PRODUCT INFORMATION

Uniprot ID	Q7Z6A9
Common Name	Icatolimab;JS-004;JS004;JS 004;JS-4;JS4;JS 4;TAB-004;TAB004;TAB 004;TAB-4;TAB4;TAB 4
Conjugate	Unconjugated
Synonyms	BTLA;BTLA1;CD272
Applications	N/A
Recommended Dilutions	N/A
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	N/A
IgG type	IgG4
Reactivity	Human
Target	BTLA
Description	Anti-BTLA(tifcemalimab biosimilar□IgG4) mAb
Delivery	3-4 weeks
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only

DIMABIO CONFIDENTIAL

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China
Telephone: +1 2409940618(USA)
/+86-18062749453(China)
/+86-400-006-0995(China)

Email: info@dimabio.com
Website: www.dimabio.com